HealthPharma & Biotech
viewFaron Pharmaceuticals Ltd

Faron Pharma gears up for “pivotal year”; bosses convinced by Traumakine’s potential

Traumakine disappointed in a late-stage ARDS study last year, but further analysis of the data showed that the drug was effective in certain patients, so another trial is in the works

cancer cell
Cancer immunotherapy Clevegen is Faron’s other major drug

Faron Pharmaceuticals Ltd (LON:FARN) boss Markku Jalkanen has told investors “there is definitely a future” for the company’s Traumakine treatment.

A phase III trial of the drug in patients with the lung inflammation condition ARDS proved a major disappointment, with Traumakine proving no more effective than a placebo.

READ: Faron to target colorectal cancer patients in ongoing Clevegen study after early promise

WATCH: Faron updates on Clevegen development as partner discussions advance

But further analysis of the data showed a “substantial reduction” in mortality in a certain subgroup of ARDS patients – those with a C/T mutation, which is carried by one-in-three Europeans.

A second phase III study is now planned, subject to approval from regulators and external funding.

“We have made a number of important discoveries whilst analysing the Traumakine INTEREST data during 2018 which have allowed us to not only believe that there is definitely a future for Traumakine in the treatment of ARDS, but also determine the next steps in its development, including the design of the phase III CALIBER study,” said chief executive Markku Jalkanen.

Clevegen showing ‘early promise’ in clinical trial

Faron’s main focus in recent months has been on Clevegen, its cancer immunotherapy which is currently undergoing a phase I/II study.

Cancer cells are notoriously good at evading detection by the immune system, but Clevegen has been designed to recognise the tumour cells and break their protective shell.

Investigators have been encouraged by the “promising early observations”, and the plan is to start enrolling more patients with late-stage colorectal cancer.

‘Pivotal year ahead’

“We were also pleased to start dosing the first patients with Clevegen in the MATINS trial, on schedule, and I am greatly encouraged by the promising early observations and data we have seen,” said CEO Jalkanen.

“I remain very optimistic about the future of Clevegen and the potential clinical benefit it may provide to late stage cancer patients.”

He added: “I believe 2019 will be a pivotal year for Faron during which we will continue to expedite Clevegen's development through clinical trials; seek approval from the FDA and the EMA on the CALIBER trial design for Traumakine whilst also advancing partnering discussions for both product candidates.”

Money in the bank

From a financial standpoint, Faron recorded a loss of €20.1mln last year (2017: loss of €21.1mln).

The company ended the period with €4.1mln (2017: €9.3mln), although this number was boosted by a €15.0mln fundraise in February and a €2.9mln placing a month later.

That cash has been set aside to support preparations for the commercialisation of Traumakine and to advance the clinical development of Clevegen in several indications.

Faron shares dropped 7.5% to 65.3p on Tuesday.

--Updates for video link and share price--

Quick facts: Faron Pharmaceuticals Ltd

Price: 129 GBX

Market: AIM
Market Cap: £50.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...



A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18


Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago

Matins Trial Update

1 week, 6 days ago

Notice of EGM

2 weeks, 4 days ago

Holdings in Company

3 weeks, 6 days ago

Interim results

4 weeks, 1 day ago

3 min read